

# Outcomes in acute pulmonary embolism (PE) and their association with adherence to international recommendations around COVID-19 pandemic-induced hospital strain before a PERT implementation in a Mexican National Institute of Health

Authors: Juan José Rodríguez-Crespo, <sup>1,</sup> Pedro Dammann-Beltrán,<sup>2,</sup> Jurhiat Alejandro Seaman-Gómez,<sup>3,</sup> Eduardo Gutiérrez-León, <sup>4,</sup> Sergio Contreras-Garduño,<sup>5,</sup> Erick Yasar Zúñiga-González, <sup>6,</sup> Thierry Hernández-Gilsoul, <sup>1,</sup> Luis Adrián Soto-Mota, <sup>3, 7,</sup> Affiliations: <sup>1</sup>Emergency Department and Continous Institutional Attention. <sup>2</sup> Department of Neurology & Psychiatry.<sup>3</sup> Metabolic Diseases Research Unit. <sup>4</sup> Department of Medical Education. <sup>5</sup> Hematology and Oncology Department. <sup>6</sup> Nephrology and Mineral Metabolism Department. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. <sup>7</sup> Tecnológico de Monterrey, School of Medicine, Mexico City, Mexico. The authors have no conflicts of interest to declare that are relevant to the content of this article.

COVID-19 season

### **BACKGROUND**

Management of patients with acute pulmonary embolism continues to be a challenge for the clinician. Lack of adherence to international recommendations leads to worse outcomes 1. During the COVID-19 pandemic, the total number and proportion of severely ill hospitalized patients raised <sup>2</sup>, consequently straining human and material resources hindering adherence to clinical guidelines. To evaluation of adherence date, recommendations before, during and shortly after the COVID-19 pandemic has not been evaluated.


## METHODS

A retrospective was performed in patients with the diagnosis of pulmonary embolism admitted to a tertiary care center in Mexico City. A balanced and randomized sample of 50 patients per year between 2019-2022 was drawn from electronic medical records and analyzed with multivariable and logistic regression models. COVID-19 season was defined as 70% or more of general floor bed occupancy in Mexico City.

We defined adherence to international recommendations based on the compliance of the items shown in Figure 1.

The primary outcome was a composite of inhospital death, hemodynamic decompensation at day 7, and in-hospital bleeding. Adherence with respect to the composite outcome was assessed using incidence rates and rate ratios according to the COVID-19 season and mortality risk for pulmonary embolism (PE), as well as the population attributable risk.

Figure 1. Illustration of adherence criteria



- Systemic thrombolysis in patients with high-risk PE.
- Any advanced treatment in patients with highrisk PE with any contraindication to systemic thrombolysis.
- Any advanced treatment in patients with intermediate-high risk PE with evidence of possible further deterioration and low bleeding risk
- Advanced treatment in patients with intermediate-high risk PE following hemodynamic deterioration.
- Use of IV UFH infusion kidney dysfunction and/or severe obesity and/or high-risk or intermediatehigh risk PE with subsequent use of some advanced treatment.
- Use of LMWH in patients without neither kidney dysfunction nor severe obesity nor in high-risk or intermediate-high risk PE with subsequent use of some advanced treatment
- Placement of inferior vena cava filter in patients with any contraindication for anticoagulation within the first 3 days of diagnosis.

#### RESULTS

No (N = 86) 54.50 49 (56.98)  70 (81.40) 7 (8.14) 9 (10.47)  22 (25.58) 19 (22.09) 4 (4.65) 29 (33.72) 7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)  43 (50.00) 20 (23.26)	Yes (N = 114) 64.00 43 (37.72)  105 (92.11) 4 (3.51) 5 (4.39)  41 (35.96) 32 (28.07) 2 (1.75) 48 (42.11) 10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.007 0.08 0.12 0.34 0.23 0.23 0.23 0.87 0.05 0.05 0.05 0.005
49 (56.98)  70 (81.40) 7 (8.14) 9 (10.47)  22 (25.58) 19 (22.09) 4 (4.65) 29 (33.72) 7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	43 (37.72)  105 (92.11) 4 (3.51) 5 (4.39)  41 (35.96) 32 (28.07) 2 (1.75) 48 (42.11) 10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.007 0.08 0.12 0.34 0.23 0.23 0.87 0.05 0.65 0.16 0.008 <0.001
70 (81.40) 7 (8.14) 9 (10.47) 22 (25.58) 19 (22.09) 4 (4.65) 29 (33.72) 7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	105 (92.11) 4 (3.51) 5 (4.39) 41 (35.96) 32 (28.07) 2 (1.75) 48 (42.11) 10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.08 0.12 0.34 0.23 0.23 0.87 0.05 0.65 0.16 0.008
7 (8.14) 9 (10.47) 22 (25.58) 19 (22.09) 4 (4.65) 29 (33.72) 7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	4 (3.51) 5 (4.39) 41 (35.96) 32 (28.07) 2 (1.75) 48 (42.11) 10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.12 0.34 0.23 0.23 0.87 0.05 0.65 0.16 0.008
7 (8.14) 9 (10.47) 22 (25.58) 19 (22.09) 4 (4.65) 29 (33.72) 7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	4 (3.51) 5 (4.39) 41 (35.96) 32 (28.07) 2 (1.75) 48 (42.11) 10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.34 0.23 0.87 0.05 0.65 0.16 0.008
9 (10.47)  22 (25.58)  19 (22.09)  4 (4.65)  29 (33.72)  7 (8.14)  9 (10.47)  5 (5.81)  15 (17.44)  19 (22.09)  34 (39.53)  27 (31.40)	5 (4.39)  41 (35.96)  32 (28.07)  2 (1.75)  48 (42.11)  10 (8.77)  4 (3.51)  5 (4.39)  12 (10.53)  10 (8.77)  18 (15.79)  14 (12.28)	0.34 0.23 0.87 0.05 0.65 0.16 0.008
22 (25.58) 19 (22.09) 4 (4.65) 29 (33.72) 7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	41 (35.96) 32 (28.07) 2 (1.75) 48 (42.11) 10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.34 0.23 0.87 0.05 0.65 0.16 0.008
19 (22.09) 4 (4.65) 29 (33.72) 7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	32 (28.07) 2 (1.75) 48 (42.11) 10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.34 0.23 0.87 0.05 0.65 0.16 0.008
19 (22.09) 4 (4.65) 29 (33.72) 7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	32 (28.07) 2 (1.75) 48 (42.11) 10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.34 0.23 0.87 0.05 0.65 0.16 0.008
4 (4.65) 29 (33.72) 7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	2 (1.75) 48 (42.11) 10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.23 0.87 0.05 0.65 0.16 0.008
29 (33.72) 7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	48 (42.11) 10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.23 0.87 0.05 0.65 0.16 0.008
7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.87 0.05 0.65 0.16 0.008 <0.001
7 (8.14) 9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	10 (8.77) 4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.05 0.65 0.16 0.008 <0.001
9 (10.47) 5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	4 (3.51) 5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.65 0.16 0.008 <0.001
5 (5.81) 15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	5 (4.39) 12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.16 0.008 <0.001
15 (17.44) 19 (22.09) 34 (39.53) 27 (31.40)	12 (10.53) 10 (8.77) 18 (15.79) 14 (12.28)	0.16 0.008 <0.001
19 (22.09) 34 (39.53) 27 (31.40) 43 (50.00)	10 (8.77) 18 (15.79) 14 (12.28)	0.008 <0.001
34 (39.53) 27 (31.40) 43 (50.00)	18 (15.79) 14 (12.28)	<0.001
27 (31.40) 43 (50.00)	14 (12.28)	
43 (50.00)		
	00 (00 04)	<0.001
	26 (22.81)	
(/		
15 (17.44)		
5 (5.55)	11 (0.00)	< 0.001
8 (9.30)	2 (1.75)	
		0.01
106.13 ± 23.22	105.63 ± 22.32	0.87
		0.001
		<0.001
		< 0.001
		<0.001
		0.37
		0.85
		0.08
		0.89
100.10 - 0.00	100.00 - 4.01	0.15
22 /27 21\	51 (44 74)	0.10
02 (07.21)	31 (44.74)	
12 /15 12\	24/21.05\	
41 (47.07)	00 (04.21)	
21 /26 OE)	E1 (44 74)	0.22
		0.001
		0.001
		0.09
	20 (23.26) 15 (17.44) 8 (9.30) 20 (23.26) 22 (25.58) 10 (11.63) 26 (30.23) 104.59 ± 37.51 106.13 ± 23.22 23.67 ± 7.18 87.06 ± 11.31 104.21 ± 382.25 11.99 ± 2.86 229.72 ± 139.65 1.40 ± 0.75 1.38 ± 1.74 136.18 ± 5.99 32 (37.21) 13 (15.12) 41 (47.67) 31 (36.05) 10 (11.63) 13 (15.12) 22 (25.58) 29/66 (43.94)	15 (17.44) 23 (20.18) 8 (9.30) 11 (9.65)  8 (9.30) 2 (1.75) 20 (23.26) 9 (7.89) 22 (25.58) 24 (21.05) 10 (11.63) 39 (34.21) 26 (30.23) 40 (35.09) 104.59 ± 37.51 119.38 ± 29.38  106.13 ± 23.22 105.63 ± 22.32 23.67 ± 7.18 28.45 ± 8.33 87.06 ± 11.31 77.83 ± 15.66 104.21 ± 382.25 126.54 ± 208.58 11.99 ± 2.86 13.63 ± 3.42 229.72 ± 139.65 246.42 ± 121.09 1.40 ± 0.75 1.79 ± 5.24 1.38 ± 1.74 1.47 ± 2.65 136.18 ± 5.99 136.30 ± 4.61  32 (37.21) 51 (44.74)  13 (15.12) 24 (21.05) 41 (47.67) 39 (34.21)  31 (36.05) 51 (44.74) 10 (11.63) 35 (30.70) 13 (15.12) 27 (23.68) 22 (25.58) 42 (36.84)





Figure 2. Stratification according to adherence and mortality risk.

Abbreviations: PE, pulmonary embolism; COVID-19s, COVID-19 season. In Panel A, adherence according to mortality risk. In Panel B, the potential number of interventions for PE per mortality risk. Panel C, the proportion of individuals is displayed according to adherence, mortality risk, and COVID-19 season



#### DISCUSSION

Our results suggest:

- 1) Routine management of patients with acute pulmonary embolism at our institution presented, in many cases, a non-adherent management regarding the use of anticoagulation, use of inferior vena cava filters, and use of advanced treatmentsGuideline adherence deviations were common.
- 2) The major risk factors for non-adherence were the presence of a higher mortality risk classification and a higher PESI score.
- 3) Non-adherent management strongly correlated with adverse in-hospital outcomes, especially during the COVID-19 pandemic-induced hospital-strain.

We found that lack of adherence was mostly presented in the next three circumstances:

- Need for any advanced treatment in patients with high-risk PE with any contraindication to systemic thrombolysis.
   Placement of inferior vena cava filters.
- 3) Use of any advanced treatment in patients with intermediate-high risk PE with further risk of hemodynamic

decompensation and with a low bleeding

risk.

#### CONCLUSION

This is the largest analysis about management appropriateness of PE patients in our country, and the only one with a balanced and randomized strategy around the COVID-19 pandemic-induced hospital-strain. Guideline adherence deviations were common. The major risk factors for non-adherence were a high mortality risk classification and a higher PESI score, non-adherent management correlated with adverse instrongly hospital outcomes, especially during the COVID-19 pandemic. Overall, our findings highlight the need of prioritizing the necessary human and material resources warrant adherence to the standards-of-care of PE patients.

### **CONTACT INFORMATION**

E-mail: juan.rodriguezc@incmnsz.mx

# REFERENCES

- 1. Jiménez D, Bikdeli B, Barrios D, et al. Management appropriateness and outcomes of patients with acute pulmonary embolism. *European Respiratory Journal*. 2018;51(5). doi:10.1183/13993003.00445-2018.
- 2. Olivas-Martinez A, Cárdenas-Fragoso JL, Jiménez JV, et al. In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. *PLoS One*. 2021;16(2February). doi:10.1371/journal.pone.0245772.